Table 3 cGVHD characteristics at belumosudil onset.
cGVHD at belumosudil onset | N = 68 |
|---|---|
cGVHD grading (NIH) (n, %) | |
Moderate | 12 (18%) |
Severe | 56 (82%) |
Organ involvement at belumosudil onset (n, %) | |
Skin | 39 (57%) |
Mouth | 28 (41%) |
Eye | 30 (44%) |
Gut | 7 (10.3%) |
Liver | 11 (16%) |
Lung | 25 (36.7%) |
Muscle and fascia | 19 (28%) |
Genitals | 8 (11.7%) |
Other | 2 (3%) |
Belumosudil dosage (n, %) | |
200 mg | 23 (34%) |
200 mg BID | 45 (66%) |
Combination with proton pump inhibitor (n, %) | 46 (68%) |
Follow-up from belumosudil onset (days, median, range) | 337 (11–830) |
Delay to best response (days, median, range) | 183 (14–560) |
Duration of belumosudil treatment (days, median, range) | 251 (11–830) |
Delay from belumosudil onset to progression or new treatment (days, median, range) | 140 (22, 506) |
Reason for belumosudil arrest (n, %) | 27 (39.7%) |
Death | 5 (18.5%) |
Complete response (end of treatment) | 4 (14.8%) |
Stable disease or progression | 12 (44.5%) |
Partial response | 1 (3.7%) |
Occlusive syndrome | 1 (3.7%) |
Toxicity | 3 (11.1%) |
Non-observance | 1 (3.7%) |
Antibiotic prophylaxis (n, %) | |
Amoxicillin or oracillin | 32 (47.5%) |
macrolide | 10 (14.5%) |
none | 26 (38%) |
Antiviral prophylaxis (n, %) | |
Valaciclovir | 63 (93%) |
Letermovir | 2 (3%) |
Entecavir | 1 (1.5%) |
Valganciclovir | 1 (1.5%) |
none | 3 (4.5%) |
Antifungal prophylaxis (n, %) | |
Posaconazole | 9 (13.2%) |
Isavuconazole | 12 (17.6%) |
